stay bullish soliri
phase data pnh due key valu driver
talk kol updat view also stress-test npv analysi
variou scenario updat analysi competit landscap see
alexion pharmaceut complement landscap analysi base
remain bullish growth prospect soliri opportun
confid alxn market leadership pnh ahu gmg
data perspect expert feedback suggest simpli need show non-inferior
soliri reflect phase design justifi regulatori approv commerci
success could address competit concern termin valu view
risk signific price compress seem overst lot work left
competitor develop subq therapi biosimilar expert discuss
brought theoret increas risk meningococc infect see low
given low incid case year patient exposur diseas
backdrop highlight kol feedback report scenario analysi overal
assess competit landscap support ow pt
npv analysi support pt assum base case non-inferior
assum modest switch soliri reflect model sotp npv
analysi valu complement worst-cas scenario
inferior soliri biosimilar take signific market share post us
eu price compress ou unrealist bear case
view sotp analysi yield complement best case
statist superior vs soliri sotp npv yield
complement overal wed argu favor risk/reward profil share
kol take market doc believ dose would
improv soliri potenti increas theoret infect risk
unlik derail trial unmet need exist pnh soliri
patient well manag doc prefer multipl treatment modal
infus subq oral studi design success pnh
quarterli annual ep usd
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
growth soliri pnh/ahu growth driven
sale refractori gmg assum
approv extend dose option
pnh ahu support long-term
viabil complement franchis addit fx
headwind macroeconom condit
greater expect growth soliri current
indic ahu pnh gmg label
expans soliri nmo posit data
rapid uptak iv
subcutan formul support upsid case
biosimilar competit soliri
time frame high price pressur ww
geographi addit failur
pnh ahu increas fx headwind
macroeconom issu support downsid case
kol view competit unmet need pnh
physician feedback gener posit see dose signific
improv even similar efficaci soliri potenti concern
increas infect risk frame expect go near-term read out
estim could earli april naiv trial may/jun
switch trial spoke expert pnh involv multipl clinic
trial across complement space experi soliri one expert
direct experi phase trial
overal physician indic follow regard soliri on-going pnh
trial unmet need therapeut provid less frequent dose
maintain control breakthrough hemolysi approxim patient
inadequ control on-label dose soliri requir dose
mg naiv trial could bias toward trend better efficaci
given known issu dose interv soliri switch trial less
like bia patient requir stabl dose ldh
uln believ potenti risk higher rate mening
thought antibodi bind directli immunoglobulin protect
meningococc infect play earli trial could risk
phase ideal profil would longer act agent possibl subq
option prevent breakthrough hemolysi reduc risk seriou sepsi
biosimilar option soliri would welcom mainli ou believ might
compet price option avail overal pnh
trial like succeed given need hit non-inferior vs soliri
physician concern potenti increas infect risk
view surpris take-away discuss potenti increas
risk meningococc infect accord physician
increas risk due greater suppress complement soliri
similar rather reflect mechan bind differ soliri
accord kol differ thought impact immunoglobulin
protect mening infect vaccin prophylaxi may effect
patient prophylact antibiot could use would remov infect
risk risk infect significantli elev indic would
cautiou start new patient switch eculizumab-experienc patient
one physician indic anxiou potenti risk increas
meningococc infect
highlight risk increas infect theoret case
sepsi report phase figur figur detail first case
third case extens studi time data present
difficult quantifi moment one physician indic risk
reveal phase trial real world use could impact switch patient
soliri risk may outweigh benefit less frequent dose
speak compani continu believ infect risk similar
soliri inde three case meningococc infect
patient year data present rate line seen soliri
alexion continu believ meningococc risk elev inhibit
rang soliri abl block
present similar risk infect
treatment-emerg advers event studi cohort
judg investig possibl probabl definit relat treatment
detail case meningococc infect studi
could slightli better prevent breakthrough hemolysi due refin
dose especi naiv trial neither trial naiv switch
power superior physician spoke believ could see breakthrough
hemolysi trend favor naiv trial clinic practic approxim
patient adequ control label dose soliri mg
follow load phase mg qw week trend like replic
soliri arm naiv phase trial switch trial patient alreadi therapi
requir stabl dose breakthrough hemolysi like limit number
patient requir higher soliri dose manag diseas standard definit
breakthrough hemolysi ldh rise uln long patient achiev ldh
symptom sign intravascular hemolysi drop hemoglobin
g/dl bl hemoglobin major advers vascular event recent present
figur saw variabl rate breakthrough hemolysi
patient across cohort phase dose significantli higher see figur vs
phase trial believ breakthrough hemolysi worst line soliri
like better naiv trial overal look phase data kol
believ naiv switch trial pnh like succeed given
known profil soliri efficaci observ phase trial
cohort seriou teae relat seriou teae teae relat teaesa sepsi infect meningococc infectionstwo patient studi experienc meningococc infect present sepsi patient male cohort whose blood cultur grew penicillin-resist serogroup patient male cohort whose blood cultur grew serogroup patient receiv penicillin prophylaxi meningococc isol intermedi sensit penicillin patient vaccin acwi vaccin patient complet recov follow iv ceftriaxon continu receiv studi barclay
hemolysi primari endpoint ldh normal breakthrough hemolysi day
physician still would like multipl option treat pnh despit want multipl option
treat pnh conced soliri real option moment
like follow spoke use alnylam product achiev
success combin soliri focu current appear ahu vs
pnh stall develop indic
biosimilar still earli physician unsur would play
eculizumab biosimilar avail overal biosimilar avail physician
singl payer system believ would mandatori use biosimilar vs soliri
option pursu biosimilar speak
compani get sens eculizumab core compani overal
biosimilar strategi kol could specul whether payer
would forc use biosimilar eculizumab also avail believ
alexion would advantag came price either soliri
asset develop earli yet interest includ achillion
factor data asset akari ra pharma mix
physician spoke describ ideal product one least compar
efficaci vs soliri also requir either less frequent infus abil dose
subcutan safeti specif risk sepsi also import increas risk
vs soliri could potenti limit uptak indic would benefici
asset subq limit variabl drug serum concentr
cohort protocol-specifi ldh reduct bl mean level u/l mean normal normal n/n uln n/n uln n/n hemolysi breakthrough hemolysi day n/n mg load mg mg load mg mg load mg mg day dose mg day thereaft barclay
expert highlight probabl one product ideal
treatment pnh patient want subcutan formul would want
product prevent breakthrough hemolysi work dose say work
worst case suggest highli unlik situat base case remain
posit data given variou potenti outcom across indic
emerg competit evalu variou scenario regard complement
franchis data concentr risk remain key issu alexion
worst case scenario contribut trial failur soliri sale
us price pressur japan share loss europe/row due biosimilar
competit begin deriv worst case bear scenario valuat
scenario also assum limit termin valu soliri given clinic data
like ip protect us japan europ believ scenario unlik
view like scenario current includ risk-adjust sale pnh
ahu switch soliri case deriv total npv
support current pt assum ip protect us japan
modest headwind soliri eu best case scenario valu share
assum robust uptak probabl success
review scenario analys hold assumpt kanuma strensiq
constant also includ addit uptak sale potenti
subq formul assum uptak captur overal revenu
model also assum discount rate line peer termin valu rate
soliri metabol calcul tv growth rate vari base scenario
product includ credit soliri nmo despit potenti near-term data
given believ higher risk figur detail
base case pt support modest switch
follow approv lesser impact biosimilar competit beyond
across geographi assum soliri somewhat insul biosimilar competit
face price headwind data point view scenario assum
efficaci safeti par soliri shown non-inferior dont yet
clinic data pnh ahu continu risk adjust sale overal
assign soliri risk adjust strensiq kanuma
combin net cash
bull case bull case model acceler uptak like
show superior minimum trend favor vs soliri safeti asset
also clean infect risk line soliri also assum less impact biosimilar
follow ip expir soliri ww scenario assum full approv
pnh ahu rapid uptak includ continu patient growth market
scenario assum soliri strensiq kanuma
combin net cash
bear case worst-cas scenario situat remov npv
valuat complet assum us soliri sale japan assum despit
ip protect signific price pressur begin europ
assum biosimilar competit follow ip expir propos ip grant
reiter highli unlik scenario repres view worst-cas
situat alexion assum soliri metabol franchis
competit progress slow nois eculizumab biosimilar given near-
term data revisit competit complement landscap analysi april
see progress made seen initi data
player akari ra achillion updat substanti enough
chang think view soliri section review
recent clinic data potenti competit asset provid take potenti
impact alexion
signific updat view asid data announc
phase clinic trial biosimilar eculizumab see thought
biosimilar eculizumab threat speak compani strategi
biosimilar eculizumab part broader strategi take share innovator-
molecul market asid acknowledg exist trial link
disclos enrol progress compani discuss specif potenti
commerci eculizumab biosimilar asset figur detail statu
updat clinical-stag complement develop program also includ link
relev clinic trial tabl
recruit site
ahu trial recruit eu
data ph seen
start ph
eu trial on-going pnh
us/ japan ip provid protect biosimilar threat european ip could add
confid long-term viabil alexion franchis ip us
japan minimum eu potenti extens continu
remain confid durabl alexion complement franchiselik bolster
near-term view develop biosimilar realli asset pnh
ahu remain challeng includ sever uncertainti includ phase
trial enrol time fashion success without new safeti issu
expertis orphan categori modest commerci infrastructur
eu potenti competitor success negoti payer across eu
ultra orphan drug price use signific lever alexion manag
threat approv market biosimilar eu establish
soc soliri differenti follow-on switch rate
even success phase approv much gate factor ip
updat mostli mix demonstr difficulti pnh ahu develop
recent updat includ data akari coversin recent data phase
cobalt trial decemb follow updat februari
demonstr rapid reduct ldh uln eculizumab-na patient
complet day trial note small open-label trial make
comparison soliri difficult also limit data potenti breakthrough
hemolysi long-term efficaci coversin formul qd subcutan inject
enough improv infus view
compani disclos plan phase could difficult enrol
rigor on-going trial prior manag issu help akari case
develop coversin
ra demonstr mix efficaci phase pnh
trial saw reduct ldh uln note high instanc
breakthrough hemolysi switch cohort data report decemb see
 thought ra pharma sc phase data pnh februari
data updat similar data report decemb could see potenti use
asset patient inadequ respond eculizumab compani plan
progress asset ahu mg
omero seem pursu indic potenti implic lectin
pathway highlight phase ahu trial recruit limit earlier
phase data avail ahu compani present phase data patient
thrombot microangiopathi develop includ broader hu berger
diseas pnh program suspend
achillion factor could interest approach yet data earli
factor inhibitor target altern pathway provid differ approach
alexion akari ra mg tid dose achillion abl achiev ldh reduct
uln one patient patient treat high-dos got close
uln ultim withdrew studi reason unrel safeti day
speak compani differ mechan could interest treatment
pnh especi patient unrespons eculizumab look achillion
develop program believ could repres interest program
unmet need commerci potenti compani current work enrol
addit patient trial
alnylam develop shift away pnh ahu data
present pnh interest alnylam move develop ahu
pnh clinic proof concept data ahu expect late current
european trial link allow prior soliri treatment one physician spoke
involv trial saw interest efficaci combin
lower dose soliri believ could use therapeut
treatment pnh patient european phase trial pnh
discontinu one point potenti seriou competitor soliri howev
data updat posit compani suggest major prioriti
novartis/ morphosi explor develop tesidolumab varieti
indic includ pnh dri novartis/ morphosi current recruit
phase proof concept trial limit addit data indic trial
recruit czech republ exclud patient previous treat soliri given
multi indic approach dri transplant wet ocular pain see
meaning competitor soliri
apelli target provid altern approach soliri data
remain earli data decemb present scientif assembl
intern pnh interest group mix patient continu therapi
least month note patient pharoah also treat soliri
reduct ldh level upper limit normal rang apelli
announc abl reduc dose three patient treat
label dosingwhich positiveit difficult draw conclus
efficaci patient data paddock trial soliri naiv demonstr
posit reduct ldh within first month therapi similar coversin
qd subcutan inject given develop plan indic phase
dri could see apelli focus less orphan larger market
ophthalmolog compani still plan pnh phase given enrol
difficultli player space may challeng
roche/chugai develop pnh on-going phase trial
compos earli develop program expect roch
comment much asset know part trial intra-
patient singl ascend dose pnh patient multiple-dos studi pnh
enrol preclin data publish april accord eu clinic trial
registri trial netherland complet enrol on-going
hungari itali enrol temporarili halt germani franc kol
mention believ molecul target receptor thu
could subject theoret infect risk discuss regard
amynda current phase trial target pnh
decemb compani releas phase data support advanc
phase trial mani asset data earli draw signific
conclus make call whether signific competitor soliri
pnh achillion might better competit choic given crowd
pnh current
model valuat updat
tweak model slightli follow npv assess alexion notabl
reduc revenu expect kanuma beyond base case
soliri remain near-term slightli increas assumpt
beyond ep forecast remain figur
valuat price target base sum-of-th part npv analysi
forecast sale soliri strensiq kanuma
includ termin valu use discount rate soliri strensiq
kanuma forecast period think appropri reflect risk
portfolio termin valu assum less growth rate discount rate
deriv valu soliri share
strensiq kanuma combin net cash result
total npv share
except per op analysisoldnewoldnewr barclay
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
